FCGR2A Promoter Methylation and Risks for Intravenous Immunoglobulin Treatment Responses in Kawasaki Disease

Table 2

Means and standard deviations of the percentage of methylation detected at each CpG site in KD patients and normal controls.

Gene	CpG sites	Methylation (%)						value
		KD patients ()			Control subjects ()
		Mean	SD	95% CI	Mean	SD	95% CI
FCGR2A	A	80.61	5.06	78.90–82.33	78.92	4.42	77.05–80.78	0.1856
	B	62.75	9.51	59.54–65.97	62.31	5.13	60.15–64.48	0.8372
	C	70.16	5.61	68.26–72.06	70.22	6.26	67.57–72.86	0.9711
	D	67.82	5.10	66.10–69.55	66.49	4.69	64.51–68.47	0.3112
	E	61.51	5.87	59.52–63.49	59.84	3.57	58.33–61.35	0.2175
	F	82.16	7.24	79.71–84.61	80.24	5.87	77.76–82.72	0.2852
	G	68.66	5.43	66.82–70.49	64.36	5.35	62.10–66.62	0.0038^**
	H	43.19	11.83	39.19–47.20	34.92	4.55	33.00–36.84	0.0019^**
	I	83.74	5.75	81.79–85.68	86.56	6.73	83.72–89.40	0.0874
	J	62.30	8.20	59.52–65.07	55.12	4.98	53.01–57.22	0.0003^***
	K	67.54	7.19	65.11–69.98	66.86	5.51	64.53–69.18	0.6982

The statistical significance , .
TGCAAGCTCTGCCTCCCG^AGGTTCACG^BCCATTCTCCTGCCTCAGCCTCCCG^CAGTAGCTGGGACTATCTGCCACCG^DCG^ECCCG^F GCTAAATTTTTTTTGTATTATTAGTAGAGACG^GGGGTTTCACCG^HTGTTAGCCAGGATGGTCTCG^IATCTCCTGACCTCG^JTGATCCACCCG^K CCTTGGCCTCCCAAAG.